Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TWORK Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. AB continue of the continue of bstitute for form 1449A/PTO Complete if Knowl (Modified) Application Number 10/007,706 INFOMMATION DISCLOSURE Filing Date November 13, 2001 STANEMENT BY APPLICANT PENNER, Reinh Id First Named Inventor Group Art Unit 1645 (use as many sheets as necessary) Examiner Name Sheet 1 of 1 Attorney Docket Number A-70040-1/RFT/NBC (469324-5)

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Palentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	A1		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·				
	A2							
	A3							
	A4							
	A5							
,	A6		· · · · · · · · · · · · · · · · · · ·		 			
	A7							
	A8							
	A9				 			
	A10				 			
	A11				 			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ*		
1	B1	WO 02/14368 A2	02-21-2002	CURAGEN CORP.				
V	B2	WO 02/10391 A2	02-07-2002	MILLENNIUM PHARM.				
	B3					-		
_	B4							
	B5					-		
	B6	- , <u>.</u>			 	-		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cile No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ₀
	C1	Runnels LW, et al., "TRP-PLIK, a bifunctional protein with kinase and ion channel activities." Science. 2001 Feb 9;291(5506):1043-7.	
	C2	Ryazanov AG, et al., "Alpha-kinases: a new class of protein kinases with a novel catalytic domain." Curr Biol. 1999 Jan 28;9(2):R43-5.	
Y	C3	Yamaguchi H, et al., "Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity." Mol Cell. 2001 May;7(5):1047-57.	
	C4		
	C5		

Examiner Signature	Date Considered	6-29-08	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1111241_1.DOC

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Substitute PTO/SB/8A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Type Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known (Modified) 10/007,706 Application Number INFORMATION DISCLOSURE Filing Date November 13, 2001 STATEMENT BY APPLICANT First Named Inventor PENNER, Reinhold Group Art Unit 1645 (use as many sheets as necessary) Examiner Name 1 of 1 Attorney Docket Number A-70040-1/RFT/NBC (469324-5)

			U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan Passages — Relevant Figures Appear
	A1				-CEIVED
	A2				Man
	A3				MAR 1 7 2003
	A4				2003
	A5		 	TECH	CENTER 1600/2900
	A6				OLIVIER 1600/2900
	A7		 		
	A8				
	A9				
	A10			† 	·
	A11	-			

Sheet

FOREIGN PATENT DOCUMENTS								
Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7⁵			
B1	WO 00/65056 A2	11-2000	BETH ISRAEL DEACONESS					
B2	EP 1 048 727 A1	11-2000	EIKEN CHEMICAL					
B3					-			
B4					_			
B 5					 			
B6		<u> </u>			_			
	B1 B2 B3 B4 B5	Foreign Patent Document Country Code ³ Number ⁶ Kind Code ⁵ (if known)	Cite Foreign Patent Document Publication Date MM-DD-YYYY	Cite No.1 Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if MM-DD-YYYY Name of Patentee or Applicant of Cited MM-DD-YYYY Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant	Cite No. 1 Foreign Patent Document Country Code Number' Kind Code (if MM-DD-YYYY) Name of Patentee or Applicant of Cited Document Relevant Passages or Relevant Figures Appear B1 WO 00/65056 A2 11-2000 BETH ISRAEL DEACONESS B2 EP 1 048 727 A1 11-2000 EIKEN CHEMICAL B3 B4 B5			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials?	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	76
	C1	SANO Y, et al., "Immunocyte Ca2+ influx system mediated by LTRPC2." Science. 2001 Aug 17;293(5533):1327-30.	T
	C2	NAGAMINE K, et al., " Molecular cloning of a novel putative Ca2+ channel protein (TRPC7) highly expressed in brain." Genomics. 1998 Nov 15;54(1):124-31.	1
	СЗ	HARTENECK C, et al., "From worm to man: three subfamilies of TRP channels." Trends Neurosci. 2000 Apr;23(4):159-66.	1
	C4		<u> </u>
	C5		\dagger

Examiner Signature	m	Date Considered	6.25.07	
			Q / /	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1105996_1.DOC

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Under the Paperwork Reduction Act of 1995, no pursons

Substitute PTO/SB/8A (08-00)
Approx or use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number.

			<u> </u>	
Substitute for form 1449A/PT		Complete if Known		
			Application Number	10/007,706
		-	Filing Date	November 13, 2001
STATEMENT BY APPLICANT		First Named Inventor	PENNER, Reinhold	
			Group Art Unit	1645
(use as many	sheets as ne -	cessary)	Examiner Name	
1	of	1	Attorney Docket Number	A-70040-1/RFT/NBC (469324-5)
		II C DATI	ENT DOCUMENTS	
	FORMATIC ATEMENT	FORMATION DISC ATEMENT BY AF	Substitute for form 1449A/PTO (Modified) FORMATION DISCLOSURE ATEMENT BY APPLICANT (use as many sheets as necessary) 1	Filing Date Filing Date First Named Inventor Group Art Unit (use as many sheets as necessary) Filing Date First Named Inventor Group Art Unit Examiner Name

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	A1							
	A2				RECEIVE			
	A3				THE CEIVE			
	A4							
	A5				NOV 2 0 2002			
	A6		•		7007			
	A7				TEOU OF LEEP LOOP IS			
	A8				TECH CENTER 1600/2			
	A9				•			
	A10							
	A11							

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т*			
	B1	WO 00/40614 A3	07-2000	BETH ISRAEL DEACONESS					
	B2								
	В3								
	B4								
	B5								
	В6	<u> </u>							

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*/	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
X	C1	PERRAUD, A-L, et al., "ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology," Nature 411:595-599 (May 2001)	
N	C2	NADLER et al., "LTRPC7 is a Mg-ATP-regulated divalent cation channel required for cell viability," Nature 411:590-595 (May 2001)	
7	СЗ		T
	C4		\dagger
	C5		\dagger

/	 		
Examiner Signature	Date Considered	6-29-04	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1097671_1.DOC

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.